Zelluna’s first-in-human ZIMA-101 trial is progressing on track, with two patients treated with ZI-MA4-1 and no dose-limiting toxicities reported to date, as the company prepares for dose escalation in 2027. Alongside the clinical progress, Zelluna has been awarded a further NOK 15.6 million grant from the Research Council of Norway to support scalable, cost-efficient manufacturing of its off-the-shelf TCR-NK therapies. BioStock spoke with CEO Namir Hassan about the momentum in ZIMA-101 and the next clinical milestones.
Read the full article HERE